Your browser doesn't support javascript.
Therapeutic monoclonal antibodies for COVID-19 management: an update.
Chavda, Vivek P; Prajapati, Riddhi; Lathigara, Disha; Nagar, Bhumi; Kukadiya, Jay; Redwan, Elrashdy M; Uversky, Vladimir N; Kher, Mukesh N; Patel, Rajvi.
  • Chavda VP; Department of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad, India.
  • Prajapati R; Department of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad, India.
  • Lathigara D; Biocharecterization Lab, Intas Pharmaceutical Ltd. (Biopharma Division), Ahmedabad, India.
  • Nagar B; Pharmacy Section, L. M. College of Pharmacy, Ahmedabad, India.
  • Kukadiya J; Pharmacy Section, L. M. College of Pharmacy, Ahmedabad, India.
  • Redwan EM; Department of Biological Sciences, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Uversky VN; Therapeutic and Protective Proteins Laboratory, Protein Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications, New Borg EL-Arab, Alexandria, Egypt.
  • Kher MN; Department of Molecular Medicine and Byrd Alzheimer's Research Institute, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
  • Patel R; Department of Quality Assurance, L. M. College of Pharmacy, Ahmedabad, India.
Expert Opin Biol Ther ; 22(6): 763-780, 2022 06.
Article in English | MEDLINE | ID: covidwho-1860687
ABSTRACT

BACKGROUND:

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected more than 529 million people, and today the world is facing different mutant strains of the virus, leading to increased morbidity rates, fatality rates, and surfacing re-infections. Various therapies, such as prophylactic treatments, repurposed drug treatments, convalescent plasma, and polyclonal antibody therapy have been developed to help combat the coronavirus disease 2019 (COVID-19). AREA COVERED This review article provides insights into the basic aspects of monoclonal antibodies (mAbs) for the therapy of COVID-19, as well as its advancement in terms of clinical trial and current approval status. EXPERT OPINION Monoclonal antibodies represents the most effective and viable therapy and/or prophylaxis option against COVID-19, and have shown a reduction of the viral load, as well as lowering hospitalizations and death rates. In different countries, various mAbs are undergoing different phases of clinical trials, with a few of them having entered phases III and IV. Due to the soaring number of cases worldwide, the FDA has given emergency approval for the mAb combinations bamlanivimab with etesevimab and casirivimab with imdevimab.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Expert Opin Biol Ther Journal subject: Biology / Therapeutics Year: 2022 Document Type: Article Affiliation country: 14712598.2022.2078160

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Expert Opin Biol Ther Journal subject: Biology / Therapeutics Year: 2022 Document Type: Article Affiliation country: 14712598.2022.2078160